&w=3840&q=100)
HCLTech Q1 FY26: Net profit down 9.1% YoY to ₹3,843 cr, dividend declared
However, revenue from operations increased 8 per cent to Rs 30,349 crore in Q1FY26 Y-o-Y from Rs 28,057 crore in Q1FY25.
The board of directors also approved an interim dividend of ₹12 per share.
Shares of HCLTech closed at ₹1,619.95 apiece on the BSE on Monday.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
22 minutes ago
- India Today
LG launches next-gen OLED Evo TVs in India, also brings QLED series for 2025
For several years now if you want a top-end OLED TV, one of the choices in the market has been the Evo TVs from LG. Now, the company has launched its latest range of OLED Evo in India, along with a refreshed lineup of more mainstream QLED Evo and QLED TVs. It is important to note that LG calls its QLED technology new OLED Evo TVs have been launched in several variants. The G5 Series OLED Evo TVs are absolute top of the line televisions from LG, and they will be available in India in multiple screen-sizes, including large sizes such as 97-inch and 77-inch. Then there are the C5 series OLED Evo TVs, and finally there are B5 series OLED TVs. The difference between Evo and non-Evo OLED TVs is most likely going to be in their peak brightness, with Evo TVs able to achieve slightly higher peak brightness and able to hold this brightness longer even in warmer rooms. Another notable difference is the refresh rate. The latest Evo TVs now come with 165Hz refresh rate, something that gamers would appreciate immensely. LG says that its new TVs are powered by the company's latest Alpha AI Processor Gen2. The TVs also now come with some AI features, which may help some users get better user experience. 'With our 2025 OLEDevo and QNEDevo line-up, we are not just introducing new TVs, we are introducing smarter companions that understand our users and adapt to their preferences,' said Brian Jung, a senior director at LG Electronics India. 'Backed by our upgraded Alpha AI processor, this new range reflects our commitment to innovation and customer-centric design.'Just like the previous LG TVs, the new ones also use WebOS software. LG says that the redesigned home screen in its latest version of WebOS is more intuitive, faster, and tailored to individual profiles, allowing each user to enjoy a personalised TV says that its OLED Evo TVs will have a starting price of Rs 149,990 for the C5 series and Rs 267,990 for the G5 series. The largest of the bunch — G5 97-inch TV — will carry an MRP of Rs 2,499,990. The Regular OLED series, which is B5, will have a starting price of Rs 193,990. The QLED Evo — or QNED Evo as LG calls it — TVs will have a starting price of Rs 119,990 while the regular QLED TVs will have a starting price of Rs 74,990.- Ends
India Today
22 minutes ago
- India Today
Anthem Biosciences IPO fully booked: Should you subscribe? Check listing gains
The initial public offering (IPO) of Anthem Biosciences Ltd is getting strong attention from investors as bidding enters its final offer, which opened for subscription on July 14, aims to raise Rs 3,395 crore through a complete offer for sale (OFS) of 5.96 crore equity of July 15 (1:54 PM), the IPO was subscribed 2.40 times overall. The retail category was booked 1.66 times, while non-institutional investors (NII) showed strong interest with 6.71 times subscription. However, qualified institutional buyers (QIBs) had only subscribed 0.48 times by that price band is fixed at Rs 570 per share. The offer is entirely an OFS, which means that the company will not receive any funds from the issue. Instead, existing shareholders are selling their MARKET PREMIUM (GMP)The grey market premium (GMP) for Anthem Biosciences IPO has increased steadily. On July 15, the GMP stood at Rs 124, which suggests an estimated listing price of Rs 694 per share. This means the IPO could offer a potential gain of 21.75% over the upper price Biosciences is a contract research, development, and manufacturing organisation (CRDMO) operating in both small and large molecule spaces. It has handled over 8,000 projects and has more than 675 clients. The company currently has 242 active projects and has adopted technologies like ADC, RNAi, flow chemistry and green chemistry early on, making it a niche player in the pharmaceutical and biotech company is known for its integrated services across drug discovery, development, and manufacturing, giving it an edge in a competitive industry. It has a strong R&D focus and globally compliant infrastructure, with more than 100 successful audits over the past three BROKERAGES SAYAccording to SBI Securities, Anthem Biosciences is well placed to benefit from the fast-growing CRDMO industry. They pointed to its planned capacity expansion, strong pipeline, and history of profitable growth. SBI noted that the IPO is fairly priced when compared to its peers and recommended investors to subscribe at the cut-off price for long-term Rathi also gave a 'SUBSCRIBE' rating. It highlighted the company's strong client relationships, innovative focus on specialty ingredients and peptides, and a differentiated fee-for-service model. The report mentioned the company's profitability and growth outlook, even though the asking price implies a price-to-earnings (PE) ratio of 70.6 times based on annualised FY25 Equities' research analyst Rajan Shinde said that the IPO gives investors a chance to invest in the high-growth CRDMO segment. He added that Anthem's integrated capabilities across molecules, early adoption of advanced technologies, and strong project pipeline make it a standout in the also pointed out that although the asking valuation of 70x seems high at first, it is still below the average industry range of 80x to 90x. This gives investors a fair entry point, especially considering the company's consistent revenue growth and profit revenue rose by 34.3% in FY24 and by 30% in FY25. Net profit also recovered, jumping 22.9% in FY25 after falling 4.6% the year for the IPO will close on July 16. The allotment is expected on July 17, and the listing is likely to happen on July 21 on both the NSE and The views, opinions, recommendations, and suggestions expressed by experts/brokerages in this article are their own and do not reflect the views of the India Today Group. It is advisable to consult a qualified broker or financial advisor before making any actual investment or trading choices.)- Ends
Hans India
23 minutes ago
- Hans India
Meta's Mega AI Push: Ex-OpenAI and Apple Researchers Join Superintelligence Lab with Rs 1600 Cr Offers
In a bold move that's shaking up Silicon Valley, Meta has gone all in on artificial intelligence — not just with tech, but with talent. CEO Mark Zuckerberg has launched an all-out recruitment offensive to build a dream team under the newly formed Meta Superintelligence Lab (MSL), offering compensation packages that rival the highest in corporate history. Among the eye-catching figures is the reported Rs 1,600 crore (around $200 million) package extended to Ruoming Pang, a top AI researcher from Apple, who is now part of Meta's ambitious AGI efforts. This follows the Rs 800 crore ($100 million) offer reportedly accepted by Trapit Bansal, an ex-OpenAI scientist and one of the key contributors to the company's o-series models. These staggering offers are said to include salaries, signing bonuses, long-term stock grants, and vesting options, placing them on par with — or even above — CEO compensation at top global banks. While Meta hasn't officially confirmed the figures, the hiring spree is real. The Meta Superintelligence Lab, launched earlier this month, is led by former GitHub CEO Nat Friedman and ex-Scale AI CEO Alexandr Wang. Since its inception, the lab has already brought in at least 11 elite researchers, poached from the likes of Google DeepMind, Apple, Anthropic, and OpenAI. High-profile names include Lucas Beyer, Xiaohua Zhai, Jack Rae, and Johan Schalkwyk from Google, along with Ji Lin, Shengjia Zhao, and Jiahui Yu from OpenAI. These strategic hires are central to Meta's larger vision of developing Artificial General Intelligence (AGI) — AI systems capable of human-level cognition, reasoning, and learning. The company's renewed focus on AGI comes after what Zuckerberg reportedly considered an underwhelming response to Meta's Llama 4 model earlier this year. But Meta's investment in the future of AI doesn't stop at talent. On Monday, Zuckerberg revealed a sweeping plan to build one of the world's largest AI infrastructures. At its core is a new 'AI data supercluster' called Prometheus, expected to go live by 2026. Prometheus is just one of several 'multi-gigawatt' compute clusters in development, alongside another major system named Hyperion, which will eventually scale up to 5 gigawatts. To speed up deployment, Meta is even building temporary AI data centers in industrial tents, a move reminiscent of Elon Musk's tent-based Tesla production during the Model 3 era. These makeshift facilities, fitted with prefabricated cooling systems, are designed to get new models online quickly — even if that means temporary shutdowns during peak summer heat. The company is also pouring $14 billion into Scale AI to ensure access to premium training datasets — a crucial component for advancing AI models toward AGI. Meta's unprecedented salary packages, infrastructure expansion, and elite hires send a clear signal: Zuckerberg is serious about leading the next frontier of AI.
